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ABSTRACT
Objective Differentiating idiopathic Parkinson’s disease
from atypical parkinsonian syndromes is challenging,
especially in the early stages. We assessed whether the
Revised Addenbrooke’s Cognitive Examination (ACE-R)
could differentiate between parkinsonian syndromes and
reﬂect longitudinal changes in cognition in these
disorders.
Methods The ACE-R was administered at baseline and
after approximately 18 months to 135 patients with
parkinsonian disorders: 86 with idiopathic Parkinson’s
disease (PD), 30 with progressive supranuclear palsy
(PSP), 19 with corticobasal degeneration (CBD). We
assessed differences between groups for ACE-R, ACE-R
subscores and Mini Mental State Examination (MMSE)
scores at baseline (analyses of variance, receiver
operating characteristics curves), and the interaction
between diagnosis and change in ACE-R scores between
visits (analyses of variance).
Results The ACE-R verbal ﬂuency subscore
distinguished between PSP and PD with a high
sensitivity (0.92) and speciﬁcity (0.87); total ACE-R score
and the visuospatial subscore were less speciﬁc (0.87
and 0.84 respectively) and sensitive (0.70 and 0.73).
Signiﬁcant group level differences were found between
PD and PSP for MMSE and ACE-R (total score and
subscores for attention and concentration, ﬂuency,
language, and visuospatial function), and between PD
and CBD for the ACE-R visuospatial subscore.
Performance worsened between visits for ACE-R score in
PD (p=0.001) and CBD (p=0.001); visuospatial
subscore in PD (p=0.003), PSP (p=0.022) and CBD
(p=0.0002); and MMSE in CBD (p=0.004).
Conclusions We propose the ACE-R, particularly the
verbal ﬂuency subscore, as a valuable contributor to the
differential diagnosis of parkinsonian syndromes in the
correct clinical context. The ACE-R may reﬂect disease
progression in PD and CBD.
INTRODUCTION
Idiopathic Parkinson’s disease (PD) can be difﬁcult
to distinguish from atypical parkinsonian syn-
dromes such as progressive supranuclear palsy
(PSP) and corticobasal degeneration (CBD), espe-
cially in the early stages of disease. A simple test
that is easy to administer, differentiates between
parkinsonian disorders and identiﬁes decline over
time would be a welcome addition to the clinical
and research armoury. For clinicians such a test
could reduce the high rate of uncertainty,
diagnostic delay and misdiagnosis, which are espe-
cially common for PSP.
In research, the urgent need for new disease mea-
sures and better diagnostic differentiation is high-
lighted by current progress toward neuroprotective
and disease-modifying therapies: early diagnosis
and the ability to monitor progression will be
increasingly important with disease-speciﬁc treat-
ments.1 A perfect single test may not exist, but a
combination of clinical, cognitive and biological
tests, as biomarkers of disease, would provide a sig-
niﬁcant step forward.2 In this study, we consider the
potential role of cognitive tests for these purposes.
PD, PSP and CBD are all movement disorders with
varying patterns of cognitive impairment. PD is char-
acterised by asymmetric bradykinesia, with tremor,
rigidity and/or postural instability. While frontostriatal
executive impairments are common in PD, an early
dementia is uncommon and tends to be heralded by
deﬁcits in posterior cortically based cognitive func-
tions.3 PSP typically presents with symmetrical
akinesia and rigidity, early falls and a supranuclear
gaze palsy. It is associated with a frontal dysexecutive
syndrome, impaired ﬂuency, disinhibition and cogni-
tive inﬂexibility, together with impairments in lan-
guage, motivation, emotional and social cognition.4–6
CBD is highly variable, but includes the alien limb
syndrome, asymmetric dystonia, apraxia, myoclonus,
non-ﬂuent aphasia and visuospatial impairment.7
Cognitive involvement in CBD ranges from near
normal cognition to severe dementia, although lan-
guage syndromes such as non-ﬂuent aphasia are
common.6 8
Despite characterisation of individual cognitive
proﬁles, the difference between diseases has been
less well studied. Cognitive tests have been sug-
gested to differentiate between PD and atypical par-
kinsonism.9 10 A small study using a battery of
executive tests, including verbal ﬂuency, correctly
identiﬁed 15 of 16 patients with PSP from those
with PD or multiple system atrophy, but with wide
CIs. The Revised Addenbrooke’s Cognitive
Examination (ACE-R) and verbal ﬂuency have been
found to distinguish between atypical parkinsonian
disorders and Alzheimer’s disease.11 However, this
is rarely a clinical conundrum; the more common
clinical dilemma is one of differentiating PD from
other parkinsonian disorders.
Imaging techniques have also been used to
distinguish between PD and atypical parkinsonism.
Typical signs such as the ‘humming bird’ and
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‘mickey mouse’ signs may occur in PSP while formal quantiﬁca-
tion of structural MRI changes using voxel-based morphometry
have suggested patterns of atrophy that may help distinguish
between PD and PSP12 with a speciﬁcity of 84% and sensitivity
of 79% based on atrophy in the cerebellar peduncles and mid-
brain.13 Contrasting atrophy patterns are also seen between
CBD and PSP; presence of midbrain atrophy has a speciﬁcity of
96.2% and sensitivity of 93.8% to distinguish PSP from CBD,
and from asymmetrical cortical atrophy a speciﬁcity of 87.5%
and sensitivity of 100%.14 A more quantitative approach was
less successful, achieving a positive predictive value (PPV) of
66.7% for PSP and 71.4% for CBD by measuring changes in
the midbrain, pontine tegementum and left frontal eye ﬁeld.15
Given the cost and limited success of brain imaging to distin-
guish PD from other parkinsonian syndromes, attention has
turned to simpler neuropsychological measures. The ACE-R is a
comprehensive and easily administered pen and paper test of
cognition which has been used in a number of neurodegenera-
tive diseases, including PD, Alzheimer’s disease16 and fronto-
temporal dementia.17 It consists of a 100-point test divided into
ﬁve cognitive subdomains (table 1).
Based on the differing published descriptions of cognitive
proﬁles between diseases, we set out to assess whether the
ACE-R, the ACE-R subscores or the widely used Mini Mental
State Examination (MMSE) might be useful in two distinct
ways. First, whether these cognitive tests distinguish between
PD, PSP and CBD, at a group average level and in terms of
receiver operator characteristic (ROC) curves. Second, whether
these tests have the potential to monitor disease progression
over time in these disorders.
METHODS
Patient recruitment
We recruited patients with PD (n=86), PSP (n=30) and CBD
(n=19). Patients with PD were newly diagnosed and recruited
as part of a community-based incidence study of PD in
Cambridgeshire (PICNICS study). All PICNICS study participants
who had returned for a follow-up assessment at the time of data
analysis were included in this study, representing 37% of the
overall PICNICS study population. Patients were recruited from
primary and secondary care and assessed using a battery of cogni-
tive and neurological tests, in addition to a semi-structured inter-
view. All patients fulﬁlled Queen Square Brain Bank criteria for PD.
Patients with PSP and CBD were recruited from a regional tertiary
referral specialist clinic at the Cambridge University Hospitals NHS
Trust (Addenbrookes), UK. This clinic encourages regional referral
of all cases of PSP and CBD, from movement disorders specialists
and memory clinics. It is not restricted to those with dementia or
cognitive impairment. Standard diagnostic criteria were applied
for PSP18 and CBD.8 Of nine PSP patients who proceeded to
post mortem, all had neuropathological conﬁrmation of PSP. All
patients gave written, informed consent and ethical approval was
obtained from the Cambridge 2 Research Ethics Committee,
Cambridge, UK.
Data collection
Cognitive assessment using the ACE-R and MMSE was performed
on two separate occasions, at a baseline visit and again at a
follow-up visit. For patients with PD, a planned visit at approxi-
mately 18 months was arranged as part of the PICNICS study. For
patients with PSP and CBD, the clinic visit closest to 18 months
follow-up was identiﬁed. Assessment was carried out in a quiet
room by investigators familiar with the ACE-R. Collection of data
in patients with PSP and CBD began before widespread use of the
Movement Disorder Society Uniﬁed Parkinson’s Disease Rating
Scale (MDS-UPDRS); therefore motor function was assessed using
the original UPDRS III, whereas patients with PD were evaluated
with the MDS-UPDRS III.
Statistical analysis
Between-group differences at baseline were investigated using a
one-way analysis of variance (ANOVA). Follow-up scores were
normalised to a time interval of 18 months. Group difference
for change in scores between visits was assessed using a multiple
measures ANOVA with ﬁxed and random effects. If appropriate
(as indicated in the results section), signiﬁcance values were
Bonferroni corrected for multiple comparisons. All statistical
analyses were performed in R statistical software (V.2.14.1;
http://cran.r-project.org/).
ROC curves and associated statistics were generated using the
pROC package.19 An optimal threshold for each cognitive test
per pairwise comparison was identiﬁed using a ‘closest top-left’
algorithm: CIs were obtained for the area under the curve
(AUC), sensitivity and speciﬁcity by a stratiﬁed bootstrap ana-
lysis with 5000 permutations. Sensitivity was deﬁned as the
ratio between true positives and all those who carried a diagno-
sis of interest (condition positive) for a given threshold.
Speciﬁcity was deﬁned as the proportion of false negatives
among all those who did not carry the diagnosis of interest
(condition negative) for a given threshold. PPV was deﬁned as
the ratio between the number of true positive subjects and the
total number of positive results (false positive and true positives)
for each diagnosis at a given threshold; Negative predictive
value (NPV) was deﬁned as the ratio between the number of
true negative results and the total number of negative results for
each diagnosis at a given threshold.
RESULTS
Demographics
Demographic details are shown in table 2. Patients with CBD
were younger than those with PD (p=0.004) and those with
Table 1 The ACE-R test multiple cognitive domains, summed to
a score of 100 points
Cognitive domain Abilities tested Score
Attention and concentration Orientation 18
Registration
Attention and concentration
Recall
Memory Anterograde memory (name and address) 26
Retrograde memory
Recall (long delay)
Recognition
Verbal fluency Letter fluency (p-words) 14
Category fluency (animals)
Language Comprehension 26
Repetition
Naming
Semantic knowledge
Visuospatial Copying drawings 16
Drawing a clock face
Perception
The MMSE is extracted as a 30-point score from elements of the ACE-R.
ACE-R, Addenbrooke’s Cognitive Examination Revised; MMSE, Mini-Mental State
Examination.
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PSP (p=0.001). PSP and PD groups did not differ in age
(p=0.3). The duration of symptoms reported by the patient or
carer at the ﬁrst clinical assessment was shorter for patients with
PD compared with those with PSP (p=0.003) and CBD
(p<0.001). There were no signiﬁcant differences between
groups in terms of baseline education, handedness or gender.
ACE-R scores and subscores for each group are shown in
ﬁgure 1. There was a trend toward more patients with PD
taking levodopa than the other two groups, although those that
did took a similar dose. Patients with PD were seen for
follow-up on average at 19.0 months, slightly later than PSP
(16.1 months, p=0.007) or CBD (14.3 months, p=<0.001).
Cognitive scores at baseline and follow-up are summarised in
ﬁgure 1. The selection of patients with PD matched the demo-
graphics of the whole PICNICS study population in terms of
age, gender, handedness, years of education, MDS-UPDRS III,
levodopa equivalent dose and ACE-R score (p>0.1 in all cases).
Diagnostic differentiation at baseline
At the baseline visit, a between-group comparison showed a sig-
niﬁcant effect of diagnosis on the ACE-R score for attention and
concentration, ﬂuency, language and visuospatial subscores, but
not for memory subscores (table 3).
To investigate the effect of disease duration and delayed
diagnosis between groups, we took advantage of a feature in
Figure 1 ACE-R scores and subscores at baseline and follow-up visits for patients with PD, PSP and CBD. ACE-R, Addenbrooke’s Cognitive Examination
Revised; CBD, corticobasal degeneration; MMSE, Mini Mental State Examination; PD, Parkinson’s disease; PSP, progressive supranuclear palsy.
Table 2 Demographics for the study population recorded at the
baseline visit
PD PSP CBD p
Age (years) 69.0 70.9 62.0 0.005
Gender (men/women) 58/30 13/17 10/9 0.2
Handedness (right/left/ambidextrous) 74/13/1 29/1 16/3 0.5
Years of education 11.9 12.0 13.0 0.3
UPDRS III (on therapy) - 29.7 29.0 0.8
MDS-UPDRS III (on therapy) 30.5 – – –
Duration of symptoms at baseline (years) 1.8 3.2 3.1 <0.0001
Percentage on dopaminergic therapy 45.3 18.1 30 0.05
Mean levodopa dose of those on
medication (mg)
273.6 220.0 266.7 0.7
p Values based on F tests in one-way analysis of variance, or χ2, as appropriate.
CBD, corticobasal degeneration; PD, Parkinson’s disease; PSP, progressive
supranuclear palsy.
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our data, that the time from ﬁrst reported symptom in the PD
group at follow-up (3.3 years) was not signiﬁcantly different
from the baseline symptom duration in the PSP (3.2 years) and
CBD (3.1 years) groups. Hence, baseline PSP and CBD scores
and follow-up PD scores were at similar symptom duration, and
could be compared directly. ANOVA results for this comparison
showed a similar pattern of signiﬁcance in group differences,
except that pairwise comparison of visuospatial scores were
non-signiﬁcant between PD and PSP (p=0.1), and between PD
and CBD (p=0.2).
To investigate the predictive accuracy of each score for individ-
ual subjects, we performed ROC curve analysis (ﬁgure 2).
Detailed results are shown in table 3 for all ACE-R scores and
subscores where the AUC exceeded 0.85, and for the MMSE as a
comparison. Best differentiation was seen between PD and PSP
subjects, in particular the verbal ﬂuency subscore. Subdividing
the ﬂuency score into letter and category components showed a
diagnostic differentiation between PD and PSP similar to the
combined scaled score using letter ﬂuency alone (threshold 7
words per minute, AUC 0.93, speciﬁcity 0.85, sensitivity 0.83,
PPV 0.81, NPV 0.93), and slightly poorer differentiation using
category ﬂuency (threshold 13.5 words per minute, AUC 0.89,
speciﬁcity 0.81, sensitivity 0.83, PPV 0.63, NPV 0.93).
Measuring change over time
An interaction between diagnosis and change in score between
visits was seen in the ACE-R total score, visuospatial subscore,
attention and concentration subscore, and MMSE (table 4). Post
hoc t tests showed that ACE-R total scores declined signiﬁcantly
in PD and CBD (see table 5). The decline was greatest in CBD.
There was greatest decline in visuospatial subscores in the CBD
group, although the PD and PSP groups also showed a signiﬁ-
cant fall. Only the CBD group showed a signiﬁcant decline in
MMSE between visits. Analysis of follow-up scores without nor-
malisation for interval to follow-up showed an almost identical
pattern of signiﬁcance, the only difference being a marginally
signiﬁcant difference for ACE-R score between visits in the PSP
group (p=0.04).
DISCUSSION
Our data show that the ACE-R, and in particular its total score,
verbal ﬂuency and visuospatial subscores, distinguish between
PD and PSP, and to a lesser extent between PD and CBD. The
differentiation between PD and PSP using verbal ﬂuency alone
(speciﬁcity 0.92, sensitivity 0.87) outperforms previous reports
of diagnostic differentiation achieved using imaging methods
alone.12 13 In addition, our data suggest that the ACE-R may be
helpful for tracking disease progression over time, particularly
in CBD. These ﬁndings suggest that in the appropriate clinical
context, the ACE-R may provide useful information in the diag-
nosis and tracking of parkinsonian disorders.
The good PPVs and NPVs, low cost and simplicity of these
cognitive biomarkers makes them especially useful when the cost
and expertise required for routine clinical MRI or positron emis-
sion tomography is prohibitive. This includes many regions of
the world where imaging is not available.20 Cognitive tests have
the potential of being safe, inexpensive and low-tech additions to
the diagnostic armoury that can be used in a range of clinical set-
tings—primary, secondary or tertiary care and research studies.
The ACE-R has even been validated in a number of languages,
although our ﬁndings would require replication in different
populations to properly assess generalisation.17 21 22
Different parts of the cognitive assessment had different value
in the differentiation of PD, PSP and CBD. We focused on the
ACE-R rather than the MMSE, as it was superior in differentiat-
ing disorders (see ROC curves, ﬁgure 2) and was more sensitive
to decline over time. The role of verbal ﬂuency was particularly
striking. Fluency deﬁcits have been described in PD,23 PSP5 24
and CBD.25 The decline in ﬂuency is not entirely due to brady-
kinesia, as ﬂuency requires very little motor function.
Interestingly, patients with PSP or CBD may generate a small
number of low-frequency words (eg, ‘peramubulator’) rather
than high-frequency words (eg, ‘put’, ‘people’). This is sup-
ported by evidence from functional imaging suggesting that
verbal ﬂuency is associated with activation of a diffuse cortical
network26 but with an emphasis on Brodmann area 45 for
lexical retrieval and Brodmann area 46 in phonological process-
ing during word generation.27 Patients with brain lesions in the
left dorsolateral frontal lobe were found to have impaired verbal
ﬂuency if there were additional or solitary striatal lesions.28
Neuropathology studies conﬁrm that both of these sites are
affected in PSP and CBD.29 30 Verbal ﬂuency impairment has
previously been reported in the early stages of PD,3 and is con-
sistent with the Braak staging hypothesis that predicts frontal
lobe cortical pathology.31
Changes in higher visual processing are present in all three
disorders, but take different forms in each. Patients with PD
may experience hallucinations or misperceptions—usually later
in the disease process—that may be related to medication side
effects or impaired attentional processing.32 Patients with CBD
and, to a lesser extent, those with PSP perform poorly on visuo-
spatial tasks. Patients with PSP are impaired more with ‘object
decision’ tasks, thought to be related to impairment in the
ventral stream of visuospatial processing, whereas patients with
CBD are typically worse on spatial location tasks, thought to
relate to the parietal atrophy disrupting the dorsal stream of
visuospatial processing.33 These previous ﬁndings are in broad
agreement with our results. The ACE-R visuospatial tests rely
more on spatial abilities than object recognition and is therefore
likely to be more sensitive to the changes seen in CBD and PSP,
but is less likely to detect the misperceptions more commonly
experienced in PD.
Table 3 Between group differences at baseline visit for ACE-R
score and subscores, and combined raw verbal fluency (combined
letter and category fluencies)
DF F p
Post hoc t test p values
PD vs
PSP
PD vs
CBD
PSP vs
CBD
ACE-R 2 18.4 <0.0001* <0.0001* 0.08 ns
MMSE 2 18.6 <0.0001* 0.002* ns ns
Attention/
concentration
2 28.6 <0.0001* 0.01* ns ns
Memory 2 3.4 ns
Fluency 2 51.7 <0.0001* <0.0001* 0.07 0.02*
Language 2 13.9 <0.0001* 0.01* ns ns
Visuospatial 2 0.5 <0.0001* 0.005* 0.02* ns
Combined fluency
score
2 30.64 <0.0001* <0.0001* ns 0.04*
Post hoc t tests are shown wherever analysis of variance showed a significant group
difference.
*Significant Bonferroni corrected p values <0.05. ns=not significant, p>0.1.
ACE-R, Addenbrooke’s Cognitive Examination Revised; CBD, corticobasal
degeneration; MMSE, Mini Mental State Examination; PD, Parkinson’s disease;
PSP, progressive supranuclear palsy.
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Statistically signiﬁcant group differences in test scores do not
necessarily indicate clinically meaningful differences in test
scores, especially in large studies. For many of our results, we
suggest that the differences between groups and over time are
both statistically signiﬁcant and clinically meaningful. MMSE
scores declined by 2.7 points in the CBD group, which is close
to the SD of 2.8 found in a large dementia population,34 sug-
gesting this change is clinically signiﬁcant. Large absolute differ-
ences were seen in PSP and CBD groups for total ACE-R score
(PSP 6.0, CBD 10.9, of maximum score 100) and visuospatial
subscores (PSP 2.5, CBD 3.8, of maximum 16 points). Although
we do not have functional rating scales or measures of activities
Figure 2 Receiver operating
characteristics curves distinguishing
between diagnostic groups using
baseline ACE-R scores and subscores.
Thresholds were chosen using a ‘top
left corner’ algorithm. CIs are shown
for sensitivity and speciﬁcity. ACE-R,
Addenbrooke’s Cognitive Examination
Revised; AUC, area under the curve;
CBD, corticobasal degeneration;
MMSE, Mini Mental State
Examination; PD, Parkinson’s disease;
PSP, progressive supranuclear palsy.
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of daily living, we suggest that the magnitudes of these changes
are likely to be clinically signiﬁcant. In contrast, the PD group
showed much smaller changes in total ACE-R score (1.9 points)
and the visuospatial subscore (0.5 points), which lie within the
range of test variation (inter-rater variance and test–retest) and
are less likely to be clinically meaningful. In the context of PD,
it has recently been demonstrated that the ACE-R reﬂects func-
tional changes; the authors could identify the difference
between cognitively well patients with PD and those with PD
and mild cognitive impairment using a cut-off of 89 (speciﬁcity
of 84%, sensitivity 69%).35 Our ﬁndings would support the use
of cognitive measures in diagnostic criteria, although neuro-
pathological correlation would be required to conﬁrm this.
In comparing groups in this study, we are reliant on clinical
diagnostic criteria, which may not always reﬂect underlying
pathology. Clinical diagnostic criteria for PSP18 tend to be
speciﬁc, with a diagnostic accuracy of 92% in patients meeting
criteria.36 They may be insensitive to PSP pathology in patients
with a PD-like syndrome37 or no clinical disease.38 In our
cohorts, many patients with PSP had consented to brain dona-
tion in a regional brain bank, providing neuropathological con-
ﬁrmation in nine out of nine cases, in keeping with the high
clinicopathological correlations in other centres.
There are several current clinical diagnostic criteria for CBD,
recently reviewed by Mathew et al.8 They applied clinical cri-
teria in early CBD, ﬁnding sensitivities of 23.5–67.5%, increas-
ing to 87.5–92.5% in later stage disease depending on the
criteria applied. Diagnostic uncertainty is further reﬂected in
the ante-mortem misclassiﬁcation of CBD from post-mortem
studies.39 40 Our ﬁndings therefore support the use of cognitive
measures in diagnostic criteria for PD, PSP and CBD, although
further neuropathological correlation would be helpful to
Table 4 ROC characteristics for between diagnostic group comparisons at optimal thresholds, determined using a ‘closest top left’ algorithm
Threshold Specificity (95% CI) Sensitivity (95% CI) PPV NPV
PSP vs PD
ACE-R 83.5 0.87 (0.80 to 0.94) 0.70 (0.53 to 0.87) 0.66 0.89
MMSE 27.5 0.80 (0.72 to 0.88) 0.67 (0.50 to 0.83) 0.54 0.87
Fluency 7.5 0.93 (0.87 to 0.98) 0.87 (0.73 to 0.97) 0.81 0.95
Combined raw fluencies 20.5 0.89 (0.81 to 0.95) 0.87 (0.73 to 0.97) 0.74 0.95
Visuospatial 14.5 0.84 (0.77 to 0.92) 0.73 (0.57 to 0.87) 0.63 0.90
CBD vs PD
ACE-R 87 0.77 (0.67 to 0.85) 0.74 (0.53 to 0.89) 0.41 0.93
MMSE 25.5 0.94 (0.88 to 0.99) 0.37 (0.16 to 0.58) 0.58 0.87
Fluency 8.5 0.83 (0.74 to 0.91) 0.63 (0.42 to 0.84) 0.44 0.91
Combined raw fluencies 24.5 0.76 (0.66 to 0.84) 0.68 (0.47 to 0.89) 0.40 0.91
Visuospatial 13.5 0.92 (0.85 to 0.98) 0.68 (0.47 to 0.89) 0.65 0.93
PSP vs CBD
ACE-R 79.5 0.63 (0.42 to 0.84) 0.63 (0.47 to 0.80) 0.73 0.52
MMSE 27.5 0.58 (0.37 to 0.79) 0.67 (0.5 to 0.83) 0.71 0.52
Fluency 7.5 0.58 (0.37 to 0.79) 0.87 (0.73 to 0.97) 0.81 0.97
Combined raw fluencies 16.5 0.79 (0.58 to 0.95) 0.67 (0.5 to 0.83) 0.83 0.60
Visuospatial 10.5 0.26 (0.11 to 0.47) 0.9 (0.8 to 1.0) 0.70 0.45
Corresponding ROC curves are shown in figure 2.
ACE-R, Addenbrooke’s Cognitive Examination Revised; CBD, corticobasal degeneration; MMSE, Mini Mental State Examination; NPV, negative predictive value; PD, Parkinson’s disease;
PPV, positive predictive value; PSP, progressive supranuclear palsy; ROC, receiver operating characteristics.
Table 5 Group differences for the change in ACE-R and subscores between baseline and follow-up visit scores, normalised to a rate of change
over 18 months
DF F p
Mean scores at baseline and follow-up
PD PSP CBD
Baseline Follow-up p Baseline Follow-up p Baseline Follow-up p
ACE-R 2 8.2 0.009* 90.1 88.0 0.04* 75.5 69.5 0.05 79.3 68.4 0.001*
MMSE 2 8.0 0.007* 28.5 28.1 0.1 26.0 25.1 ns 26.0 25.1 0.004*
Attention/concentration 2 6.3 0.04* 17.7 17.4 ns 16.4 15.5 ns 16.2 14.3 ns
Memory 2 1.2 ns 21.5 21.6 19.6 18.3 19.5 18.9
Fluency 2 4.0 ns 10.8 10.3 5.1 4.1 8.3 6.5
Language 2 2.6 ns 24.9 24.0 22.0 21.0 23.1 20.4
Visuospatial 2 15.5 <0.0001* 15.3 14.8 0.003* 12.4 9.9 0.02* 12.1 8.3 0.0002*
Combined raw fluencies 2 4.7 ns 29.5 29.6 14.6 12.3 23.4 18.9
UPDRS III 29.7 35.9 ns 29.1 36.2 ns
MDS-UPDRS III 30.5 41.0 <0.001*
*Significant Bonferroni correct p value <0.05. ns=not significant, p>0.1.
ACE-R, Addenbrooke’s Cognitive Examination Revised; CBD, corticobasal degeneration; MDS-UPDRS III, Movement Disorder Society Unified Parkinson’s Disease Rating Scale III;
MMSE, Mini Mental State Examination; PD, Parkinson’s disease; PSP, progressive supranuclear palsy.
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investigate the link between cognition and histological disease
changes in more detail, and evaluating cognitive differentiation
of atypical or intermediate syndromes which combine features
of PD, PSP and CBD.
In principle, one could apply more detailed neuropsycho-
logical tests. However, an advantage of the ACE-R is ease of
use, requiring short training for those administering it. Usually a
full test will take around 10 min in cognitively well participants
without akinesia, although it can be up to half an hour in
severely affected patients with PSP and CBD. Verbal ﬂuency is
an even briefer test, taking just 2 min of testing time. The
ACE-R and verbal ﬂuency could be assessed routinely in a
general neurology or movement disorders clinic and its utility
has been shown in this study.
There are however several limitations to our study. The
number of patients and follow-up time was limited.
Furthermore, the duration of symptoms was shorter in the PD
group, although correcting for this by comparing baseline PSP
and CBD scores with follow-up PD scores led to the same
pattern of results. Delayed diagnosis in PSP and CBD is
common, with patients often receiving an alternative diagnosis
for 1–2 years, therefore recruiting patients with PSP and CBD at
an earlier stage is challenging. We cannot exclude the possibility
that cognitive proﬁles would be different and between-group
differences smaller at an earlier stage in the disease processes.
Post-mortem conﬁrmation of diagnosis was not available in all
patients and so it is possible that for a small number of patients
the diagnosis may be inaccurate. Patients with PD were seen for
follow-up slightly later than the other two groups. However,
correcting for this difference would augment rather than dimin-
ish our ﬁndings given the largest differences over time were
seen in the CBD group who had the shortest mean follow-up.
Low scores may arise for different reasons in the three
groups. For example, it is possible that apraxia or other features
of a movement disorder impaired task performance differen-
tially between groups, particularly on visuospatial drawing tasks
and in patients with CBD. However, the majority of subjects
were relatively early in the disease course, able to hold a pencil
and draw sufﬁciently to reveal the cognitive elements of the test.
There are also caveats to our use of the UPDRS III motor sub-
scale to measure motor severity. This scale does not capture all
signs in the CBD phenotype, omitting apraxia, alien limb phe-
nomena, dysarthrophonia and mirror movements. Although the
principal axial and appendicular motor signs of PSP are
included in the UPDRS III, it should be borne in mind that the
test was developed for use in PD and that it may not be
adequately balanced to sensitively grade the progressive severity
of PSP or CBD. The use of the UPDRS should therefore be seen
as descriptive and not diagnostic of our study populations.
Concluding remarks
We propose that the ACE-R score and verbal ﬂuency are useful
in supporting the differential diagnosis of parkinsonian disor-
ders, including the sometimes difﬁcult differentiation between
PD and PSP. By the time of diagnosis (approximately 3 years
from symptom onset for PSP), patients with PSP had lower
ACE-R scores and severely reduced verbal ﬂuency. The ACE-R
may additionally be useful for measuring disease progression,
especially in CBD, both in the clinical setting and in clinical
trials of new therapies.
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